The Role of Tumor Suppressor DLC-1: Far From Clear

Title:The Role of Tumor Suppressor DLC-1: Far From Clear

Volume: 17 Issue: 7

Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng*Dong-Sheng Pei*

Affiliation:

• Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China

• Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu,China

Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.

Abstract: Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).

Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria.

Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1.

Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.

Cite this article as:

Liu Xu, Pan Yao-Jie, Zheng Jun-Nian*, Pei Dong-Sheng*, The Role of Tumor Suppressor DLC-1: Far From Clear, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160907142754

DOI https://dx.doi.org/10.2174/1871520616666160907142754	Print ISSN 1871-5206
Publisher Name Bentham Science Publisher	Online ISSN 1875-5992